Stockscreener 앱 받기
0.7989
12.74%
0.0903
시장 영업 전:
.80
0.0011
+0.14%
전일 마감가:
$0.7086
열려 있는:
$0.74
하루 거래량:
36.66M
Relative Volume:
3.82
시가총액:
$215.41M
수익:
$2.02M
순이익/손실:
$-97.59M
주가수익비율:
-1.3901
EPS:
-0.5747
순현금흐름:
$-102.38M
1주 성능:
-4.81%
1개월 성능:
-38.55%
6개월 성능:
-21.68%
1년 성능:
-62.32%
1일 변동 폭
$0.6725
$0.8189
1주일 범위
$0.61
$0.86
52주 변동 폭
$0.5469
$2.82
Humacyte Inc Stock (HUMA) Company Profile
명칭
Humacyte Inc
전화
919-313-9633
주소
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
0.7989 | 191.07M | 2.02M | -97.59M | -102.38M | -0.5747 |
VRTX
Vertex Pharmaceuticals Inc
|
499.65 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
631.81 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
912.46 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
192.62 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.52 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-27 | 개시 | Barclays | Overweight |
| 2025-05-14 | 재개 | H.C. Wainwright | Buy |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2023-12-11 | 개시 | H.C. Wainwright | Buy |
| 2023-08-14 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-16 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | 개시 | Cowen | Outperform |
| 2021-09-24 | 개시 | Oppenheimer | Outperform |
| 2021-09-22 | 개시 | BTIG Research | Buy |
| 2021-09-16 | 개시 | Piper Sandler | Overweight |
모두보기
Humacyte Inc 주식(HUMA)의 최신 뉴스
Humacyte Announces $50 Million Public Offering of Common Stock - Global Legal Chronicle
HUMA stock plunges after-hours on proposed share offering even as dialysis data impresses - MSN
Here's Why Humacyte, Inc. (HUMA) Fell More Than Broader Market - MSN
Enterprise value to revenue forward of Humacyte, Inc. – NASDAQ:HUMA - TradingView
Price to earnings forward of Humacyte, Inc. – NASDAQ:HUMA - TradingView
Humacyte (HUMA) Stock Fair Value Falls As Split Analyst Views Follow V012 Data - Yahoo Finance
Price to earnings forward of Humacyte, Inc. – BOATS:HUMA - TradingView
Humacyte, Inc. (HUMA) latest stock news and headlines - Yahoo Finance Singapore
Price to book forward of Humacyte, Inc. – BOATS:HUMA - TradingView
Price to sales forward of Humacyte, Inc. – BOATS:HUMA - TradingView
Enterprise value to revenue forward of Humacyte, Inc. – BOATS:HUMA - TradingView
Humacyte, Inc. Actuals & Estimates (NASDAQ:HUMA) - TradingView
Enterprise value to EBITDA forward of Humacyte, Inc. – BOATS:HUMA - TradingView
HUMA Forecast — Price Target — Prediction for 2027 - TradingView
Humacyte Inc (HUMAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Humacyte Inc (HUMA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BTIG Maintains Humacyte(HUMA.US) With Buy Rating, Cuts Target Price to $2 - Moomoo
Form 13G Humacyte For: 22 June By Investing.com - Investing.com South Africa
Davidson Kempner reports 4.74% stake in Humacyte (NASDAQ: HUMA) - Stock Titan
Humacyte Inc (HUMA) Institutional Confidence - TradingKey
Humacyte Inc (HUMA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet - Yahoo Finance
Humacyte, Inc. (HUMA) dips more than broader market: What you should know - MSN
Piper Sandler Maintains Humacyte(HUMA.US) With Hold Rating, Maintains Target Price $1 - Moomoo
Humacyte Inc (HUMAW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Analysts Offer Insights on Healthcare Companies: Humacyte (HUMA) and Qiagen (QGEN) - The Globe and Mail
Humacyte Inc (HUMAW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Humacyte Inc (HUMA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Humacyte Inc (HUMA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Humacyte Inc (HUMA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Humacyte Inc (HUMAW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Humacyte Inc (HUMAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Humacyte Inc (HUMAW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Humacyte Inc (HUMAW) Institutional Confidence - TradingKey
Humacyte Inc (HUMAW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Humacyte Inc (HUMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Humacyte Inc (HUMA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Humacyte Inc (HUMA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
HUMA Maintained by TD Cowen -- Price Target Lowered to $1.25 - GuruFocus
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know - Yahoo Finance
HUMA Reiterates by BTIG -- Price Target Maintained at $2.00 - GuruFocus
Humacyte (HUMA) Barclays 28th Annual Global Healthcare Conference Summary - Quartr
Humacyte, Inc. (HUMA) surpasses market returns: Some facts worth knowing - MSN
Humacyte (NASDAQ:HUMA) reports positive Phase 3 V012 trial results - grafa.com
Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Humacyte stock rises on positive dialysis trial results By Investing.com - Investing.com India
Humacyte stock rises on positive dialysis trial results - Investing.com
Fresenius updates 6.8% Humacyte (HUMA) ownership stake disclosure - Stock Titan
Humacyte’s bioengineered vessel shows benefit for women on dialysis - Investing.com UK
Humacyte’s bioengineered vessel shows benefit for women on dialysis By Investing.com - Investing.com Nigeria
Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting - The Manila Times
Humacyte Inc (HUMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.33%
자본화:
|
볼륨(24시간):